Mike Holfinger joined Pliant Therapeutics as Vice President, CMC in March 2020 with responsibility for manufacturing, process development, analytical development, and clinical supply. Before joining Pliant, Mike was Senior Vice President, Technical Operations at Aimmune Therapeutics, where he led the technical team in the development, FDA approval, and commercial manufacture of the first treatment for peanut allergy. Mike also held senior roles in product and process development, manufacturing, and supply chain at Alexza Pharmaceuticals and Affymax. He started his career in drug substance process development at Upjohn which became part of Pfizer. At Pfizer, Mike served as a technical and regulatory liaison between drug substance manufacturing sites in Europe and Pfizer headquarters. Mike graduated from Miami University with BS degrees in Applied Science and in Chemistry. He received his doctorate degree in Chemical Engineering from University of Wisconsin-Madison.